Professor Ann Daly
Professor of Pharmacogenetics

  • Email:
  • Telephone: +44 (0) 191 208 7031
  • Address: Institute of Cellular Medicine
    Medical School
    Newcastle University
    Newcastle upon Tyne NE2 4HH

BA (Class 2.1) in Biochemistry (1978, University of Dublin)

PhD in Biochemistry (1982, University of Dublin)

FBPhS (2012)


Present appointment

Professor of Pharmacogenetics, Institute of Cellular Medicine, Newcastle University, UK (since August 2004)


Previous appointments

Senior Lecturer, School of Clinical and Laboratory Sciences, Newcastle University (1998-2004).

Lecturer, Department of Pharmacological Sciences, Newcastle University (1992-1998).

Senior Research Associate, Department of Pharmacological Sciences, Newcastle University (1989-1992).

Research Associate, Medical Molecular Biology Group and Department of Dermatology, Newcastle University (1984-1989).

Postdoctoral Research Assistant, Department of Molecular Biology, University of Geneva, Switzerland (1982-1984).


Other current appointments

Chair IUPHAR (The International Union of Basic and Clinical Pharmacology) Drug Metabolism and Transporter section executive board (2014-2018)

Council member International Society for the Study of Xenobiotics (2012-2015)

Member IUPHAR Pharmacogenetics subcommittee (2007 onwards)

Committee member UK Pharmacogenetics and Stratified Medicine Network (since 2014)

Co-chair Meeting Organising Committee, European ISSX meeting, Glasgow, June 2015

Editor, CYP alleles website (

Editorial Board Member, Clinical Pharmacology & Therapeutics, Pharmacogenetics & Genomics, Xenobiotica, Journal of Pharmacology & Experimental Therapeutics, Pharmacogenomics, Pharmacogenomics Journal, British Journal of Clinical Pharmacology

Research Interests

Pharmacogenetic studies on the discovery of novel human genetic polymorphisms, their functional significance and their relationship to outcome of drug therapy, susceptibility to adverse drug reactions and susceptibility to complex diseases. These studies are central to the area of personalised (stratified) medicine and
a key aim is to translate our findings to simple tests that can be used to determine the most appropriate drug treatment on an individual basis.

I coordinate the iDILIC network on genetics of drug-induced liver injury ( and see also ( together with the UK DILIGEN project (